IndexIQ Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

IndexIQ Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$360K	Buy	4,683 +683	+17%	+$57.1K	0.01%	938
2021 Q4	$353K	Buy	4,000 +849	+27%	+$70.1K	0.01%	870
2021 Q3	$244K	Buy	3,151 +169	+6%	+$13.3K	0.01%	1019
2021 Q2	$249K	Buy	2,982 +93	+3%	+$7.37K	0.01%	1005
2021 Q1	$218K	Buy	2,889 +366	+15%	+$29.9K	0.01%	1007
2020 Q4	$221K	Buy	+2,523	New	+$200K	0.01%	872

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

IndexIQ Advisors's BMRN Position: Q1 2022 in Review

IndexIQ Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q1 2022, buying an estimated $57.1K and bringing the position to 4,683 shares worth $360K. The position accounts for 0.01% of the portfolio, ranked #938.

IndexIQ Advisors first reported a position in BMRN in Q4 2020 and has held it in 6 quarters since. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2022.

IndexIQ Advisors held 4,683 shares of BioMarin Pharmaceuticals worth $360K as of Q1 2022.
IndexIQ Advisors bought 683 BioMarin Pharmaceuticals shares in Q1 2022, an estimated $57.1K.
BioMarin Pharmaceuticals made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #938 holding.
IndexIQ Advisors first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.